Hostname: page-component-848d4c4894-8bljj Total loading time: 0 Render date: 2024-06-20T09:18:12.924Z Has data issue: false hasContentIssue false
  • English
  • Français

1588 – Interleukin-6 As a Biomarker Of The Model Of Staging In Bipolar Disorder

Published online by Cambridge University Press:  15 April 2020

I. Grande ,
P.V. Magalhaes ,
I. Chendo ,
L. Stertz ,
C.S. Gama ,
E. Vieta  and
F. Kapczinski
I. Grande
Affiliation:
Bipolar Disorders Program, Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain
P.V. Magalhaes
Affiliation:
Bipolar Disorder Program and Laboratory of Molecular Psychiatry, National Institute for Translational Medicine, INCT-TM Hospital de Clínicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
I. Chendo
Affiliation:
Hospital de Santa Maria, Lisboa, Portugal
L. Stertz
Affiliation:
Bipolar Disorder Program and Laboratory of Molecular Psychiatry, National Institute for Translational Medicine, INCT-TM Hospital de Clínicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
C.S. Gama
Affiliation:
Bipolar Disorder Program and Laboratory of Molecular Psychiatry, National Institute for Translational Medicine, INCT-TM Hospital de Clínicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
E. Vieta
Affiliation:
Bipolar Disorders Program, Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain
F. Kapczinski
Affiliation:
Bipolar Disorder Program and Laboratory of Molecular Psychiatry, National Institute for Translational Medicine, INCT-TM Hospital de Clínicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Different proposals of the staging model in bipolar disorder (BD) have been launched suggesting a progression from prodromal to more severe and refractory presentations. Biochemical variations in BD are receiving attention as they may help to understand the neurobiological correlates of the disorder and its neuroprogression.

Objectives

Study pro-inflammatory factors, such as interleukins along the progression of the disorder.

Aims

To investigate a) the role of interleukin-6 (IL-6) in the model of staging and b) to detect clinical predictors of variations in IL-6 levels.

Methods

This is a case-control study matched for age and gender. Patients required the diagnosis confirmation by SCID, being in euthymia (HDRS, YMRS scores ≤ 7 in last month), and were classified in Kapczinski et al. clinical stages. At the end, 109 patients and 25 controls were eligible for the study. Serum IL-6 levels were determined by ELISA.

Results

Seventy-six (69.7%) patients were female and the mean age was 44.2 (SD= 12.9) years. A significant increase in IL- 6 was found in patients compared to controls (t=2.33, p=0.02) and among the four groups of patients (F=2.85, p=0.04). Results from linear regression analysis revealed that number of episodes per year, age at first episode, and age were significantly associated with IL-6 (β=0.025, CI: 0.005-0.044, p=0.012; β=-0.016, CI:(-0.031)-(-0.001),p=0.033; β=0.042, CI:0.027-0.058, p=0.0001, respectively).

Conclusions

Interleukin-6 may be a useful biomarker in the model of staging in bipolar disorder and could be related to the number of episode per year and early onset of the disorder.

Type
Abstract
Information
European Psychiatry , Volume 28 , Issue S1: Abstracts of the 21th European Congress of Psychiatry , 2013 , 28-E874
Copyright
Copyright © European Psychiatric Association 2013
Submit a response

Comments

No Comments have been published for this article.